Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible

Vaccine

Volumn 27, Issue 18, 2009, Pages 2469-2474

  Gelinck, L B S ^a   van den Bemt, B J F ^b   Marijt, W A F ^a   van der Bijl, A E ^a   Visser, L G ^a   Cats, H A ^b   Rimmelzwaan, G F ^c   Kroon, F P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Dept of Pharmacy ^*  (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anti TNF; Hematologic stem cell transplantation; HIV; Intradermal influenza vaccination

Indexed keywords

INFLUENZA VACCINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ERYTHEMA; FEASIBILITY STUDY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SKIN MANIFESTATION;

ADULT; AGED; ANTIBODIES, VIRAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 62749155284     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.053     Document Type: Article

References (46)

1. Fiore A.E., Shay D.K., Haber P., Iskander J.K., Uyeki T.M., Mootrey G., et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 56 RR-6 (2007) 1-54
2. Kyle S., Chandler D., Griffiths C.E., Helliwell P., Lewis J., McInnes I., et al. British Society for Rheumatology Standards Guidelines Audit Working Group (SGAWG). Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology 44 (2005) 390-397
3. Werkgroep antiretrovirale behandeling van de Nederlandse Vereniging van Aids Behandelaren. [Revised guideline "Antiretroviral Treatment"]. Ned Tijdschr Geneeskd 2005;149(43): 2399-405.
4. Ljungman P. Immunization of transplant recipients. Bone Marrow Transplant 23 7 (1999) 635-636
5. Gelinck L.B., van der Bijl A.E., Beyer W.E., Visser L.G., Huizinga T.W., van Hogezand R.A., et al. The effect of anti-tumor necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 67 (2008) 713-716
6. Kroon F.P., van Dissel J.T., de Jong J.C., Zwinderman K., and van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 18 26 (2000) 3040-3049
7. Avetisyan G., Ragnavölgyi E., Toth G.T., Hassan M., and Ljungman P. Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients. Bone Marrow Transplant 36 5 (2005) 411-415
8. Ljungman P., Nahi H., and Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol 130 1 (2005) 96-98
9. Pauksen K., Linde A., Hammarström V., Sjölin J., Carneskog J., Jonsson G., et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin Infect Dis 30 2 (2000) 342-348 [Erratum in: Clin Infect Dis 2000;30(6):992]
10. Magnani G., Falchetti E., Pollini G., Reggiani L.B., Grigioni F., Coccolo F., et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant 24 5 (2005) 588-592
11. O'Hagan D.T. Recent advances in vaccine adjuvants for systemic and mucosal administration. J Pharm Pharmacol 50 1 (1998) 1-10
12. Glenn G.M., and Kenney R.T. Mass vaccination: solutions in the skin. Curr Top Microbiol Immunol 304 (2006) 247-268
13. Yu R.C., Abrams D.C., Alaibac M., and Chu A.C. Morphological and quantitative analyses of normal epidermal Langerhans cells using confocal scanning laser microscopy. Br J Dermatol 131 6 (1994) 843-848
14. Berman B., Chen V.L., France D.S., Dotz W.I., and Petroni G. Anatomical mapping of epidermal Langerhans cell densities in adults. Br J Dermatol 109 5 (1983) 553-558
15. Glenn G.M., Kenney R.T., Ellingsworth L.R., Frech S.A., Hammond S.A., and Zoeteweij J.P. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev Vaccines 2 2 (2003) 253-267
16. Palache A.M., Beyer W.E., Lüchters G., Völker R., Sprenger M.J., and Masurel N. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature. Vaccine 11 9 (1993) 892-908
17. Goodeve A., Potter C.W., Clark A., Jennings R., Schild G.C., and Yetts R. A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection. J Hyg (Lond) 90 1 (1983) 107-115
18. Palache A.M., Beyer W.E., and Osterhaus A.D. Influenza vaccine dosages. Vaccine 26 19 (2008) 2305-2306
19. Appleby J.C., Himmelweit F., and Stuart-Harris C.H. Immunisation with influenza virus vaccines: comparison of intradermal and subcutaneous routes. Lancet 30 (1951) 1384-1387
20. McCarroll J.R., and Kilbourne E.D. Immunization with Asian-strain influenza vaccine: equivalence of subcutaneous and intradermal routes. N Engl J Med 259 13 (1958) 618-621
21. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351 22 (2004) 2286-2294
22. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., and Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351 22 (2004) 2295-2301
23. La Montagne J.R., and Fauci A.S. Intradermal influenza vaccination-can less be more?. N Engl J Med 351 22 (2004) 2330-2332
24. Wyatt K.N., Ryan G.J., and Sheerin K.A. Reduced-dose influenza vaccine. Ann Pharmacother 40 9 (2006) 1635-1639
25. Auewarakul P., Kositanont U., Sornsathapornkul P., Tothong P., Kanyok R., and Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 25 4 (2007) 659-663
26. Belshe R.B., Newman F.K., Wilkins K., Graham I.L., Babusis E., Ewell M., et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25 37-38 (2007) 6755-6763
27. Payler D.K., and Skirrow M.B. Letter: intradermal influenza vaccination. Br Med J 2 5921 (1974) 727
28. Treanor J. Weathering the influenza vaccine crisis. N Engl J Med 351 20 (2004) 2037-2040
29. Khanlou H., Sanchez S., Babaie M., Chien C., Hamwi G., Ricaurte J.C., et al. The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunodeficiency virus-positive patients. Arch Intern Med 166 13 (2006) 1417
30. Redfield R.R., Innis B.L., Scott R.M., Cannon H.G., and Bancroft W.H. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine: a cost reduction strategy. JAMA 254 22 (1985) 3203-3206
31. Macroepidemiology of Influenza Vaccination (MIV) Study Group. The macro-epidemiology of influenza vaccination in 56 countries, 1997-2003. Vaccine 23 44 (2005) 5133-5143
32. Ryan J., Zoellner Y., Gradl B., Palache B., and Medema J. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 24 47-48 (2006) 6812-6822
33. Smedley J., Poole J., Waclawski E., Stevens A., Harrison J., Watson J., et al. Influenza immunisation: attitudes and beliefs of UK healthcare workers. Occup Environ Med 64 4 (2007) 223-227
34. CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR 2005;54(RR-17).
35. Beyer W.E., Palache A.M., Luchters G., Nauta J., and Osterhaus A.D. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?. Virus Res 103 (2004) 125-132
36. Holland D., Booy R., De Looze F., Eizenberg P., McDonald J., Karrasch J., et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 198 5 (2008) 650-658
37. Estcourt M.J., Létourneau S., McMichael A.J., and Hanke T. Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. Eur J Immunol 35 9 (2005) 2532-2540
38. Kilbourne E.D. Intradermal vaccination against influenza. N Engl J Med 352 10 (2005) 1044
39. Dombrecht E.J., Aerts N.E., Schuerwegh A.J., Hagendorens M.M., Ebo D.G., Van Offel J.F., et al. Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis. Clin Exp Rheumatol 24 1 (2006) 31-37
40. Macatonia S.E., Lau R., Patterson S., Pinching A.J., and Knight S.C. Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. Immunology 71 1 (1990) 38-45
41. Collin M.P., Hart D.N., Jackson G.H., Cook G., Cavet J., Mackinnon S., et al. The fate of human Langerhans cells in hematopoietic stem cell transplantation. J Exp Med 203 1 (2006) 27-33
42. Fabrizi F., Dixit V., Magnini M., Elli A., and Martin P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther 24 3 (2006) 497-506
43. Ristola M.A., Vuola J.M., Valle M., and von Reyn C.F. Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects. Vaccine 23 2 (2004) 205-209
44. Kamoltham T., Thinyounyong W., Phongchamnaphai P., Phraisuwan P., Khawplod P., Banzhoff A., et al. Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe. J Pediatr 151 2 (2007) 173-177
45. Chiu S.S., Peiris J.S., Chan K.H., Wong W.H., and Lau Y.L. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 119 6 (2007) 1076-1082
46. Manuel O., Humar A., Chen M.H., Chernenko S., Singer L.G., Cobos I., et al. Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant 7 11 (2007) 2567-2572